SIGRID THERAPEUTICS
DEAD

Serial Number

88873084

Owner

Sigrid Therapeutics AB

Attorney

Bradley L. Cohn

Filing Date

Apr 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SIGRID THERAPEUTICS Trademark

Serial Number: 88873084

SIGRID THERAPEUTICS is a trademark filed by Sigrid Therapeutics AB on April 15, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Sigrid Therapeutics AB (5 trademarks)

Birger Jarlsgatan 57

Entity Type: 98

Trademark Details

Filing Date

April 15, 2020

Registration Date

Not Registered

Published for Opposition

August 25, 2020

Goods & Services

Dietetic preparations adapted for medical use; dietetic substances in the nature of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions adapted for medical use; pharmaceuticals and natural remedies for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; preparations for use in naturopathy for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; nutritional supplements; chemical preparations for medical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and chemico- pharmaceutical preparations for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; dietary and nutritional supplements; health food supplements for persons with special dietary requirements; chemical preparations for pharmaceutical purposes for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; pharmaceutical preparations and substances for glycemic control; pharmaceutical preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietetic preparations and substances for glycemic control; dietetic preparations and substances for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; dietary and nutritional supplements for glycemic control; dietary and nutritional supplements for the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in glycemic control; pharmaceutical preparations in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions for use in the prevention and treatment of prediabetes, diabetes and for the improvement of overall metabolic health; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, colitis; pharmaceutical preparations and substances, dietary and nutritional substances in the form of tablets, capsules, liquid formulations, drinks, shots, shakes, gels, powders and suspensions, all for use in the treatment and regulation of intestinal injury or inflammation, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients, and not including products primarily for use in the treatment of angina pectoris and high blood pressure

Surgical and medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; capsulated medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; medical devices for the treatment and prevention of obesity and being overweight, and for use in weight control; medical devices for the treatment and prevention of prediabetes, diabetes and glycemic control, and for the improvement of overall metabolic health; medical devices for use in the prevention and treatment of prediabetes and diabetes; orally administered medical devices for the treatment and prevention of obesity, being overweight, prediabetes, diabetes, glycemic control and for the improvement of overall metabolic health; surgical and medical devices, capsulated devices and orally administered medical devices all for use in the treatment and regulation of obesity, body weight, body fat, body composition, body weight circumference, cholesterol and LDL cholesterol levels, liver disease, steatohepatitis, infantile colic, gut microbiota, insulin levels and resistance, blood lipids, diarrhea, constipation, intestinal injury or inflammation, colitis, Crohn's disease, cardiovascular risk factors, post bariatric surgery patients

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 20, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 20, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2023 EXRA
SOU EXTENSION 5 GRANTED
Mar 14, 2023 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 14, 2023 AITU
SOU EXTENSION 5 FILED
Mar 2, 2023 EXT5
SOU TEAS EXTENSION RECEIVED
Mar 2, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 10, 2022 EXRA
SOU EXTENSION 4 GRANTED
Sep 8, 2022 EX4G
SOU EXTENSION 4 FILED
Sep 8, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 8, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2022 EXRA
SOU EXTENSION 3 GRANTED
Feb 7, 2022 EX3G
SOU EXTENSION 3 FILED
Feb 7, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 7, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 8, 2021 EXRA
SOU EXTENSION 2 GRANTED
Oct 6, 2021 EX2G
SOU EXTENSION 2 FILED
Oct 6, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 6, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 16, 2021 EXRA
SOU EXTENSION 1 GRANTED
Apr 14, 2021 EX1G
SOU EXTENSION 1 FILED
Apr 14, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 14, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 20, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 25, 2020 NPUB
PUBLISHED FOR OPPOSITION
Aug 25, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 5, 2020 NONP
ASSIGNED TO LIE
Jul 20, 2020 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 17, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 17, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 17, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 17, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 17, 2020 CNEA
ASSIGNED TO EXAMINER
Jul 6, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 24, 2020 NWOS
NEW APPLICATION ENTERED
Apr 18, 2020 NWAP